Lakewood-Amedex Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LABT | BDRX | ACXP | ONCO | ELAB | PMCB | |
|---|---|---|---|---|---|---|
| Market cap | 453.56K | 1.41M | 5.64M | 3.88M | 1.55M | 4.09M |
| P/E (TTM) | — | 0.0 | — | 0.0 | — | — |
| Forward P/E | — | — | -0.6 | -0.8 | — | -1.0 |
| Price/book | 0.1 | 0.0 | 0.6 | 0.2 | 0.1 | 0.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −99.78% | −98.73% | −80.19% | −99.63% | −99.85% | −61.58% |
| Today | −1.85% | −4.61% | +0.98% | +15.69% | −1.03% | +12.03% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LABT news ›Lakewood-Amedex Biotherapeutics Inc. Announces Positive Minimum Inhibitory Concentration Data From Recent Clinical Isolates For Nu-3
Lakewood-Amedex Biotherapeutics Inc. announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being investigated... announced positive Minimum…
Lakewood-Amedex Biotherapeutics Inc Announces Positive Data For The Advancement of Lead Candidate Nu-3 In Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc. announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly... announced positive data for its lead…
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin Compounds
Lakewood-Amedex Biotherapeutics Inc. announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin compounds that are being explored... announced the expansion of the…
News from Lakewood-Amedex Biotherapeutics Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Lakewood-Amedex Biotherapeutics Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.…
Lakewood-Amedex Biotherapeutics Inc. Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity And Low Potential For Resistance At IDWeek 2026
Lakewood-Amedex Biotherapeutics Inc. announced the presentation of research highlighting the antimicrobial profile of Nu-3, the Company's lead clinical candidate, at IDWeek 2026. The poster, titled, ... announced the presentation of…
HC Wainwright Initiates Coverage on Lakewood-Amedex Biotherapeutics With Buy Rating
... Biotechnology & Medical Research HC Wainwright Initiates Coverage on Lakewood-Amedex Biotherapeutics With Buy Rating Published on 10/28/2026 at 08:23 am EDT
Lakewood-Amedex Biotherapeutics, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Lakewood-Amedex Biotherapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time LABT price, Nasdaq stock exchange Relative Strength Chart Lakewood-Amedex Biotherapeutics, Inc. Biotechnology & Medical…
Lakewood-Amedex Biotherapeutics announces agreement with PERI to serve as CRO for Phase 2 clinical trial of Nu-3
Lakewood-Amedex Biotherapeutics Inc: Lakewood-Amedex Biotherapeutics announces agreement with PERI to serve as CRO for Phase 2 clinical trial of Nu-3 ... Biotechnology & Medical Research Lakewood-Amedex Biotherapeutics announces agreement…
Lakewood-Amedex Biotherapeutics, Inc.(NasdaqCM: LABT) added to S&P TMI Index
Lakewood-Amedex Biotherapeutics, Inc. added to S&P TMI Index... Biotechnology & Medical Research Lakewood-Amedex Biotherapeutics, Inc.(NasdaqCM:LABT) added to S&P TMI Index Latest news about Lakewood-Amedex Biotherapeutics, Inc. Chart…
Lakewood-Amedex Biotherapeutics Inc. Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
Lakewood-Amedex Biotherapeutics Inc. announced positive preclinical data in urinary tract infection and pulmonary infection indications in animal models treated with Bisphosphocin® compounds. In an... announced positive preclinical data in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- prnewswire.com2
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.